Oligonucleotide Synthesis Market

SKU: DMPH2649 | Last Updated On: Sep 30 2022 | Available Formats

> Global Oligonucleotide Synthesis Market Expected to reach a high CAGR of 13.79% during the forecast period 2022-2029: DataM Intelligence

Global Oligonucleotide Synthesis Market is segmented By Product (Reagents, Equipment, Synthesized Oligonucleotides (Oligonucleotide-based drugs, Primers, Probes, Large-scale synthesized oligonucleotides, Others)), By Application (Research  (PCR, QPCR, Sequencing, Gene Synthesis, Others), Diagnostics, Therapeutics (DNA & Antisense oligonucleotide-based Therapies, RNAi Oligonucleotide-based Therapies, CpG Oligonucleotide-based Therapies)), By End-User (Hospitals, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Diagnostic Laboratories), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029


Market Overview

[195 Pages Report] The global oligonucleotide synthesis market size was valued at US$ YY billion in 2022 and is estimated to reach US$ YY billion by 2029, growing at a CAGR of 13.79% during the forecast period (2022-2029). 

Oligonucleotide synthesis is the chemical synthesis of relatively short fragments of nucleic acids with a defined chemical structure. The technique is extremely useful in current laboratory practice because it provides rapid and inexpensive access to custom-made oligonucleotides of the desired sequence.

oligonucleotide synthesis market Scope



Market CAGR


Segments Covered

By Product, By Application, By End User, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other vital insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To know more insights into the Market, Get Our Sample Brochure

Market Dynamics

The global oligonucleotide synthesis market growth is driven by its extensive use for the selection and determination of DNA sequences (hybridization probes or affinity purification), gene construction, and site-directed mutagenesis.

Increasing research activities in the pharmaceutical and biotechnology sectors The increasing prevalence of chronic and life-threatening diseases has prompted pharmaceutical companies and research firms to focus on R&D activities for the development of effective therapeutics. As a result, advances in life sciences research are leading to an improved understanding of biological systems. The development of oligonucleotide synthesis technologies has helped pharmaceutical and biotechnology researchers with molecular-level development, design, and modification of biological systems. The increasing research activities in the pharmaceutical and biotechnology sectors will lead to the expansion of the global oligonucleotide synthesis market.

Increasing focus on new oligonucleotide therapies will drive the market growth Pharmaceutical and biotechnological companies are focusing on the R&D of new oligonucleotide drugs due to the presence of a limited number of approved drugs. Oligonucleotides efficiently target disease-relevant proteins and genes that are inaccessible by small-molecule drugs and biological drugs. Recent advances have helped overcome challenges associated with the administration, cellular uptake, biodistribution, and side effects of oligonucleotide therapies. Currently, many oligonucleotide therapeutics are in various stages of clinical trials for the treatment of many diseases, including viral infections, rare genetic disorders, neural and neuromuscular conditions, and cancers. The presence of these drugs and an increase in R&D are expected to have a positive impact on the overall market growth.

Regulatory issues associated with oligonucleotide therapeutics are likely to hinder the market growth

However, regulatory issues associated with oligonucleotide therapeutics, diversity in oligonucleotide molecules, and challenges in effective oligonucleotide delivery may hamper the growth of the oligonucleotide synthesis market over the forecast period.

COVID-19 Impact Analysis

The global oligonucleotide synthesis market has received immense impetus from the COVID-19  pandemic, as stakeholders are increasingly searching for newer approaches to diagnosing and curing patients affected by COVID-19. Pioneering research and development are being undertaken by bioSynthesis, a leading vendor. It has doled out ready-to-use cocktail mixes such as the SARS-CoV-2 N1 Oligo Mix, the SARS-CoV-2 N2 Oligo Mix, and the Human RNase P (RP) Oligo Mix respectively. Such breakthroughs are generating a level of optimism amongst healthcare providers and stimulating them to keep the anti-coronavirus battle raging., hence, expected to boost the market growth over the forecast period.  

Segment Analysis

The synthesized oligonucleotides segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

Synthetic oligonucleotides in therapeutics for treating neurodegenerative diseases and cancer are anticipated to heighten market prospects. Synthetic oligonucleotides are most reliably produced using a solid synthesis approach. It allows oligonucleotides to be custom-designed to produce specific genetic sequences. To obtain the desired oligonucleotide each building block, comprising a nucleic acid is coupled sequentially to the growing chain until the desired product is achieved. Once complete the oligonucleotide chain is released from the solid support used for synthesis, deprotected and the final product purified.

It is also common to see synthetic oligonucleotides modified at the ribose sugar to form bridged nucleic acids or linked nucleic acids which is promising for antisense and silencing RNA applications, the process by which gene expression is negatively affected leading to sequence-specific gene silencing. These bridged nucleic acids lead to the formation of constrained or inaccessible oligonucleotides which introduces additional stability to the molecule. The conformational inflexibility bridging the sugar moiety brings results in a gain in binding affinity of the oligonucleotide to complementary strands of RNA and DNA.

  • Oligonucleotide-based drugs: Oligonucleotide-based drugs, in particular antisense oligonucleotides, are part of a growing number of pharmaceutical and biotech programs progressing to treat a wide range of indications including cancer, cardiovascular, neurodegenerative, neuromuscular, and respiratory diseases, as well as other severe and rare diseases. Reviewing fundamentals and offering guidelines for drug discovery and development, this book is a practical guide covering all key aspects of this increasingly popular area of pharmacology and biotech and pharma research, from the basic science behind antisense oligonucleotides chemistry, toxicology, and manufacturing, to safety assessments, the design of therapeutic protocols, to clinical experience. More than 200 unique oligonucleotide-based product candidates are currently being evaluated in various preclinical/clinical phases of development. More than 270 registered clinical trials focused on oligonucleotides, till 2019, it is worth noting that the maximum (34) number of trials were registered in 2019.
  • Probes: A probe is a small fragment of DNA or RNA used to detect the target DNA or RNA in the sample by molecular hybridization. They are also known as molecular markers. The length of the probe can vary (100 to 1000 bases), and probe nucleotides are complementary to the part of the target sequence. For ease of detection, probes are labeled with radioactive isotopes or with fluorescent dyes or antibodies. Probes bind with the complementary bases of the target sequence and reveal the presence of the target DNA or RNA in the sample. There are two main methods of labeling probes: end labeling and nick translation. Probes are categorized into different types including DNA probes, RNA probes, cDNa probes, and synthetic oligonucleotides probes, and they are prepared using different techniques.
  • Primers: Primer is a small stretch of DNA or RNA that serves as a starting point for DNA replication. This acts as a starting point for DNA synthesis. Primer anneals with the complementary bases of the DNA strands. They are generally not labeled. The target sequence is flanked by two primers known as forwarding primer and reverse primer. Specificity and complementarity are the primary factors in the design of primers. Secondary structures should also be avoided.

Hospitals are expected to dominate the global oligonucleotide synthesis market during the forecast period

The significant number of inpatient and outpatient visits in hospitals coupled with the high requirement of oligonucleotide drugs to cater to the demand from the vast patient pool suffering from diseases such as Duchenne muscular dystrophy, spinal muscular atrophy, and hepatic veno-occlusive disease, is driving the market growth in the segment.

However, in the developing countries of Asia-pacific and Africa, the hospital infrastructure is still underdeveloped which is hampering the market in the forecast period. For instance, in India, the number of hospital beds per 1,000 population is less than 1, which is well below the World Health Organization (WHO) average of around 2.7 and the Organization for Economic Co-operation and Development (OECD) average of over 5. While some of the recent investments in the hospital sector are as follows, the value of merger and acquisition (M&A) deals across hospitals jumped by a record. This factor will drive the growth of the market in the forecast period.

Geographical Analysis

The North American region holds the largest market share global oligonucleotide synthesis market

The North American region is dominating the global oligonucleotide synthesis market and accounted for the largest market share in 2020, due to the increasing R&D activities and the growing number of oligonucleotide-based drugs/therapies being approved by the FDA. The presence of innovators and key players in the U.S. has resulted in higher penetration of products in the market. Furthermore, the strong foothold of North America in genomics, proteomics, oncology, diagnostic screening, and drug discovery has significantly contributed to maintaining its large share. Government and private entities are investing in the development of academic and research infrastructure in North America. Moreover, collaboration among major players and universities for the development of novel approaches to curing chronic conditions through genetic medicine is expected to contribute to the growth of the market in the forecast period.

Competitive Landscape

The oligonucleotide synthesis market is moderately competitive with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Agilent Technologies Inc., Danaher Corp., General Electric Co., GenScript Biotech Corp., Kaneka Corp., Merck KGaA, Nitto Denko Corp., QIAGEN NV, Sarepta Therapeutics Inc., and Thermo Fisher Scientific Inc. among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the oligonucleotide synthesis market globally.  

Oligonucleotide Synthesis Market Key Companies to Watch

Thermo Fisher Scientific Inc.

Overview: Founded in 2006 and headquartered in Waltham, Massachusetts, the U.S.; Thermo Fisher Scientific Inc. is engaged in providing analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics services under the brands Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services worldwide. The company operates through four business segments, namely, Analytical Instruments, Life Sciences Solutions, Laboratory Products and Services, and Specialty Services. The company provides oligonucleotide products through Invitrogen, under the life Sciences solutions business segment.

With its subsidiaries and a strong network of distribution, the company has a presence across North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Product Portfolio: The Company’s portfolio comprised its lead Iodine-Water-Pyridine-Tetrahydrofuran Oxidizer Solution (0.02 M), Trifluoroacetic Acid (TFA) Neat Liquid, in addition to Trichloroacetic Acid Dichloromethane, Deblocking Solution targeting high-performance reagents begin with raw materials that must conform to strict specifications.

Key Development: In February 2019, Thermo Fisher Scientific agreed with BioNTech (Germany). Under the terms of this agreement, BioNTech's messenger RNA (mRNA) manufacturing platform will be supported by Thermo Fisher through the supply of nucleotides, enzymes, and other critical raw materials.

Trending Topics

Ankylosing Spondylitis Drugs Market

Invasive Fungal Infection Market

Proprotein Convertase Subtilisin/Kexin Type 9 Market


What is the Growth Rate of the oligonucleotide synthesis market?

Growing at a CAGR of 13.79% during the forecast period (2022-2029). 

What Companies Are Included in the oligonucleotide synthesis market?

Sarepta Therapeutics Inc., Thermo Fisher Clinical, GenScript Biotech, Merck KGaA, Nitto Denko, Danaher Corp., and Agilent Technologies are among the fundamental players adding to the expansion of the industry.

What is The COVID-19 Impact on the oligonucleotide synthesis market?

Some global market for oligonucleotide activity has taken tremendous attention as a result of the recent COVID 21 pandemic. BioSynthesis, a leading seller, is conducting pioneering research and development. It has doled away ready-to-work with cocktail mixes such as the SARS CoV 2 N1 oligo mix, and the Human RNase P( RP) Oligo Mix.

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!